PT3649124T - ¿compostos de fluoropiperidina como antagonistas puros do recetor 5-ht6 - Google Patents
¿compostos de fluoropiperidina como antagonistas puros do recetor 5-ht6Info
- Publication number
- PT3649124T PT3649124T PT187738323T PT18773832T PT3649124T PT 3649124 T PT3649124 T PT 3649124T PT 187738323 T PT187738323 T PT 187738323T PT 18773832 T PT18773832 T PT 18773832T PT 3649124 T PT3649124 T PT 3649124T
- Authority
- PT
- Portugal
- Prior art keywords
- pure
- receptor antagonists
- fluoropiperidine
- compounds
- fluoropiperidine compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201741028024 | 2017-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3649124T true PT3649124T (pt) | 2021-06-01 |
Family
ID=63678636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT187738323T PT3649124T (pt) | 2017-08-07 | 2018-08-06 | ¿compostos de fluoropiperidina como antagonistas puros do recetor 5-ht6 |
Country Status (26)
Country | Link |
---|---|
US (1) | US10973831B2 (pt) |
EP (1) | EP3649124B1 (pt) |
JP (1) | JP6808088B2 (pt) |
KR (1) | KR102190332B1 (pt) |
CN (1) | CN111051302B (pt) |
AU (1) | AU2018313049B2 (pt) |
BR (1) | BR112020002227A2 (pt) |
CA (1) | CA3071084C (pt) |
CY (1) | CY1124174T1 (pt) |
DK (1) | DK3649124T3 (pt) |
EA (1) | EA202090397A1 (pt) |
ES (1) | ES2874628T3 (pt) |
HR (1) | HRP20210822T1 (pt) |
HU (1) | HUE055186T2 (pt) |
IL (1) | IL272287B (pt) |
LT (1) | LT3649124T (pt) |
MA (1) | MA50036B1 (pt) |
MD (1) | MD3649124T2 (pt) |
MX (1) | MX2020001311A (pt) |
PL (1) | PL3649124T3 (pt) |
PT (1) | PT3649124T (pt) |
RS (1) | RS61886B1 (pt) |
SG (1) | SG11202000833YA (pt) |
SI (1) | SI3649124T1 (pt) |
WO (1) | WO2019030641A1 (pt) |
ZA (1) | ZA202000758B (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020286003A1 (en) * | 2019-05-24 | 2021-12-02 | Integrative Research Laboratories Sweden Ab | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003293653B2 (en) * | 2002-11-08 | 2009-05-14 | F. Hoffmann-La Roche Ag | Substituted benzoxazinones and uses thereof |
US7378415B2 (en) * | 2004-09-30 | 2008-05-27 | Roche Palo Alto Llc | Benzoxazine and quinoxaline derivatives and uses thereof |
US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
-
2018
- 2018-08-06 CA CA3071084A patent/CA3071084C/en active Active
- 2018-08-06 EP EP18773832.3A patent/EP3649124B1/en active Active
- 2018-08-06 PT PT187738323T patent/PT3649124T/pt unknown
- 2018-08-06 ES ES18773832T patent/ES2874628T3/es active Active
- 2018-08-06 MA MA50036A patent/MA50036B1/fr unknown
- 2018-08-06 MD MDE20200518T patent/MD3649124T2/ro unknown
- 2018-08-06 WO PCT/IB2018/055894 patent/WO2019030641A1/en unknown
- 2018-08-06 MX MX2020001311A patent/MX2020001311A/es unknown
- 2018-08-06 SI SI201830293T patent/SI3649124T1/sl unknown
- 2018-08-06 DK DK18773832.3T patent/DK3649124T3/da active
- 2018-08-06 BR BR112020002227-6A patent/BR112020002227A2/pt unknown
- 2018-08-06 HU HUE18773832A patent/HUE055186T2/hu unknown
- 2018-08-06 CN CN201880056542.7A patent/CN111051302B/zh active Active
- 2018-08-06 LT LTEP18773832.3T patent/LT3649124T/lt unknown
- 2018-08-06 JP JP2020505814A patent/JP6808088B2/ja active Active
- 2018-08-06 RS RS20210640A patent/RS61886B1/sr unknown
- 2018-08-06 EA EA202090397A patent/EA202090397A1/ru unknown
- 2018-08-06 US US16/635,893 patent/US10973831B2/en active Active
- 2018-08-06 SG SG11202000833YA patent/SG11202000833YA/en unknown
- 2018-08-06 AU AU2018313049A patent/AU2018313049B2/en active Active
- 2018-08-06 PL PL18773832T patent/PL3649124T3/pl unknown
- 2018-08-06 KR KR1020207004769A patent/KR102190332B1/ko active IP Right Grant
-
2020
- 2020-01-27 IL IL272287A patent/IL272287B/en unknown
- 2020-02-05 ZA ZA2020/00758A patent/ZA202000758B/en unknown
-
2021
- 2021-05-21 HR HRP20210822TT patent/HRP20210822T1/hr unknown
- 2021-05-25 CY CY20211100449T patent/CY1124174T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272056A (en) | Heterocyclic compounds as adenosine antagonists | |
IL276400A (en) | Dopamine D3 receptor antagonist compounds | |
IL254476A0 (en) | Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists | |
SG11202001340VA (en) | Quinoxaline derivatives as adenosine receptor antagonists | |
IL253848A0 (en) | Amine compounds as 5-hydroxytryptamine 4 receptor agonists | |
GB201702617D0 (en) | Receptor | |
PL3661941T3 (pl) | Pochodne tiazolopirydynowe jako antagoniści receptora adenozynowego | |
IL271694A (en) | Novel uses of a pure 6HT–5 receptor antagonist | |
HK1258023A1 (zh) | 純5-ht6受體拮抗劑與nmda受體拮抗劑的組合 | |
EP3350167A4 (en) | Androgen receptor Antagonist | |
SG11202001337XA (en) | Bezimidazole derivatives as adenosine receptor antagonists | |
EP3865472C0 (en) | THROMBOXAN RECEPTOR ANTAGONISTS | |
ZA202000758B (en) | Fluoropiperidine compounds as pure 5-ht6 receptor antagonists | |
HK1231414A1 (zh) | 胃輕癱用 受體激動劑 | |
EP3388423A4 (en) | NK1 RECEPTOR ANTAGONIST | |
GB201805675D0 (en) | Compounds For Use As Apelin Receptor Antagonists | |
GB201701887D0 (en) | Receptor | |
GB201700926D0 (en) | Receptor | |
GB201513871D0 (en) | Bicyclo dopamine D3 receptor antagonists | |
GB201419433D0 (en) | Dopamine D3 receptor antagonist compounds | |
GB201419430D0 (en) | Dopamine D3 receptor antagonist compounds |